AIM IMMUNOTECH INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
AIM IMMUNOTECH INC. (AIM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 5.59% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-27
- AIM IMMUNOTECH INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 5.59%, a 494.68% increase from fiscal 2023.
- AIM IMMUNOTECH INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 0.94%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 5.59% 10-K · filed 2025-03-27 |
| 2023-12-31 | 0.94% 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |